following an abbreviated submission:
vutrisiran (Amvuttra®) is accepted for use within NHSScotland.
Indication under review: For the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
Vutrisiran offers an additional treatment choice of double-stranded small interfering ribonucleic acid (siRNA) for this indication.
Another double-stranded siRNA, patisiran, has been accepted via the ultra-orphan medicine process for this indication.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice640KB (PDF)
Medicine details
- Medicine name:
- vutrisiran (Amvuttra)
- SMC ID:
- SMC2596
- Indication:
For the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
- Pharmaceutical company
- Alnylam Pharmaceuticals
- BNF chapter
- Nutrition and blood
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 11 September 2023